PD-1 expression on dendritic cells suppresses CD8+T cell function and antitumor immunity

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Lim, Tong Seng ^a,e   Chew, Valerie ^b   Sieow, Je Lin ^a   Goh, Siting ^a   Yeong, Joe Poh Sheng ^a,c   Soon, Ai Ling ^a   Ricciardi Castagnoli, Paola ^d,e  

^a AGENCY FOR SCIENCE   (Singapore)

^b Singapore Health Services   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d Genetics and Biology Innovation Pole (PoloGGB)   (Italy)

^e A Menarini Biomarkers Singapore Pte Ltd   (Singapore)

Author keywords

Antitumor immunity; cancer immunotherapy; dendritic cell; hepatocellular carcinoma; liver cancer; Programmed death one (PD 1)

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOREGULATION; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 84961666207     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1085146     Document Type: Article

References (41)

1. M.E.Keir, M.J.Butte, G.J.Freeman, A.H.Sharpe. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331.
2. Y.Ishida, Y.Agata, K.Shibahara, T.Honjo. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-95; PMID:1396582.
3. H.Nishimura, M.Nose, H.Hiai, N.Minato, T.Honjo. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11:141-51; PMID:10485649; http://dx.doi.org/10.1016/S1074-7613(00)80089-8.
4. H.Nishimura, T.Okazaki, Y.Tanaka, K.Nakatani, M.Hara, A.Matsumori, S.Sasayama, A.Mizoguchi, H.Hiai, N.Minato Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291:319-22; PMID:11209085; http://dx.doi.org/10.1126/science.291.5502.319.
5. J.Wang, T.Yoshida, F.Nakaki, H.Hiai, T.Okazaki, T.Honjo. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 2005; 102:11823-8; PMID:16087865; http://dx.doi.org/10.1073/pnas.0505497102.
6. J.Wang, I.M.Okazaki, T.Yoshida, S.Chikuma, Y.Kato, F.Nakaki, H.Hiai, T.Honjo, T.Okazaki PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 2010; 22:443-52; PMID:20410257; http://dx.doi.org/10.1093/intimm/dxq026.
7. T.Yoshida, F.Jiang, T.Honjo, T.Okazaki. PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. Proc Natl Acad Sci U S A 2008; 105:3533-8; PMID:18299579; http://dx.doi.org/10.1073/pnas.0710951105.
8. T.Okazaki, Y.Otaka, J.Wang, H.Hiai, T.Takai, J.V.Ravetch, Honjo T. Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice. J Exp Med 2005; 202:1643-8; PMID:16352741; http://dx.doi.org/10.1084/jem.20051984.
9. G.J.Freeman, A.J.Long, Y.Iwai, K.Bourque, T.Chernova, H.Nishimura, L.J.Fitz, N.Malenkovich, T.Okazaki, M.C.Byrne Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027.
10. Y.Latchman, C.R.Wood, T.Chernova, D.Chaudhary, M.Borde, I.Chernova, Y.Iwai, A.J.Long, J.A.Brown, R.Nunes PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261-8; PMID:11224527; http://dx.doi.org/10.1038/85330.
11. J.M.Chemnitz, R.V.Parry, K.E.Nichols, C.H.June, J.L.Riley. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173:945-54; PMID:15240681; http://dx.doi.org/10.4049/jimmunol.173.2.945.
12. R.V.Parry, J.M.Chemnitz, K.A.Frauwirth, A.R.Lanfranco, I.Braunstein, S.V.Kobayashi, P.S.Linsley, C.B.Thompson, J.L.Riley. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25:9543-53; PMID:16227604; http://dx.doi.org/10.1128/MCB.25.21.9543-9553.2005.
13. T.Yokosuka, M.Takamatsu, W.Kobayashi-Imanishi, A.Hashimoto-Tane, M.Azuma, T.Saito. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012; 209:1201-17; PMID:22641383; http://dx.doi.org/10.1084/jem.20112741.
14. K.A.Sheppard, L.J.Fitz, J.M.Lee, C.Benander, J.A.George, J.Wooters, Y.Qiu, J.M.Jussif, L.L.Carter, C.R.Wood PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004; 574:37-41; PMID:15358536; http://dx.doi.org/10.1016/j.febslet.2004.07.083.
15. T.Okazaki, S.Chikuma, Y.Iwai, S.Fagarasan, T.Honjo. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013; 14:1212-8; PMID:24240160; http://dx.doi.org/10.1038/ni.2762.
16. D.L.Barber, E.J.Wherry, D.Masopust, B.Zhu, J.P.Allison, A.H.Sharpe, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-7; PMID:16382236; http://dx.doi.org/10.1038/nature04444.
17. C.L.Day, D.E.Kaufmann, P.Kiepiela, J.A.Brown, E.S.Moodley, S.Reddy, E.W.Mackey, J.D.Miller, A.J.Leslie, C.DePierres PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-4; PMID:16921384; http://dx.doi.org/10.1038/nature05115.
18. L.Trautmann, L.Janbazian, N.Chomont, E.A.Said, S.Gimmig, B.Bessette, M.R.Boulassel, E.Delwart, H.Sepulveda, R.S.Balderas Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-202; PMID:16917489; http://dx.doi.org/10.1038/nm1482.
19. S.Urbani, B.Amadei, D.Tola, M.Massari, S.Schivazappa, G.Missale, C.Ferrari. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80:11398-403; PMID:16956940; http://dx.doi.org/10.1128/JVI.01177-06.
20. Y.Iwai, M.Ishida, Y.Tanaka, T.Okazaki, T.Honjo, N.Minato. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7; PMID:12218188; http://dx.doi.org/10.1073/pnas.192461099.
21. Y.Iwai, S.Terawaki, T.Honjo. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005; 17:133-44; PMID:15611321; http://dx.doi.org/10.1093/intimm/dxh194.
22. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690.
23. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, W.J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694.
24. S.Yao, Y.Zhu, L.Chen. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013; 12:130-46; PMID:23370250; http://dx.doi.org/10.1038/nrd3877.
25. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239.
26. S.J.Park, H.Namkoong, J.Doh, J.C.Choi, B.G.Yang, Y.Park, Y.Chul Sung Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol 2014; 95(4):621-9; PMID:24319287; http://dx.doi.org/10.1189/jlb.0813443
27. J.Krempski, L.Karyampudi, M.D.Behrens, C.L.Erskine, L.Hartmann, H.Dong, E.L.Goode, K.R.Kalli, K.L.Knutson. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011; 186:6905-13; PMID:21551365; http://dx.doi.org/10.4049/jimmunol.1100274.
28. S.Yao, S.Wang, Y.Zhu, L.Luo, G.Zhu, S.Flies, H.Xu, W.Ruff, M.Broadwater, I.H.Choi PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 2009; 113:5811-8; PMID:19339692; http://dx.doi.org/10.1182/blood-2009-02-203141.
29. H.Dong, S.E.Strome, D.R.Salomao, H.Tamura, F.Hirano, D.B.Flies, P.C.Roche, J.Lu, G.Zhu, K.Tamada Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c.
30. L.Carter, L.A.Fouser, J.Jussif, L.Fitz, B.Deng, C.R.Wood, M.Collins, T.Honjo, G.J.Freeman, B.M.Carreno. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002; 32:634-43; PMID:11857337; http://dx.doi.org/10.1002/1521-4141(200203)32:3%3c634::AID-IMMU634%3e3.0.CO;2-9.
31. D.M.Davis. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol 2007; 7:238-43; PMID:17290299; http://dx.doi.org/10.1038/nri2020.
32. M.Dhainaut, M.Moser. Regulation of immune reactivity by intercellular transfer. Front Immunol 2014; 5:112; PMID:24734030; http://dx.doi.org/10.3389/fimmu.2014.00112.
33. A.Ribas. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366:2517-9; PMID:22658126; http://dx.doi.org/10.1056/NEJMe1205943.
34. L.T.Nguyen, P.S.Ohashi. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol 2015; 15:45-56; PMID:25534622; http://dx.doi.org/10.1038/nri3790.
35. K.A.Hogquist, S.C.Jameson, W.R.Heath, J.L.Howard, M.J.Bevan, F.R.Carbone. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17-27; PMID:8287475; http://dx.doi.org/10.1016/0092-8674(94)90169-4.
36. P.Mombaerts, J.Iacomini, R.S.Johnson, K.Herrup, S.Tonegawa, V.E.Papaioannou. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992; 68:869-77; PMID:1547488; http://dx.doi.org/10.1016/0092-8674(92)90030-G.
37. F.Granucci, I.Zanoni, N.Pavelka, S.L.Van Dommelen, C.E.Andoniou, F.Belardelli, M.A.Degli Esposti, P.Ricciardi-Castagnoli. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med 2004; 200:287-95; PMID:15289500; http://dx.doi.org/10.1084/jem.20040370.
38. V.Chew, C.Tow, C.Huang, E.Bard-Chapeau, N.G.Copeland, N.A.Jenkins, A.Weber, K.H.Lim, H.C.Toh, M.Heikenwalder Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst 2012; 104:1796-807; PMID:23197495; http://dx.doi.org/10.1093/jnci/djs436.
39. S.McCartney, W.Vermi, S.Gilfillan, M.Cella, T.L.Murphy, R.D.Schreiber, K.M.Murphy, M.Colonna. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009; 206:2967-76; PMID:19995959; http://dx.doi.org/10.1084/jem.20091181.
40. F.V.Chisari, K.Klopchin, T.Moriyama, C.Pasquinelli, H.A.Dunsford, S.Sell, C.A.Pinkert, R.L.Brinster, R.D.Palmiter. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59:1145-56; PMID:2598264; http://dx.doi.org/10.1016/0092-8674(89)90770-8.
41. V.Chew, C.Tow, M.Teo, H.L.Wong, J.Chan, A.Gehring, M.Loh, A.Bolze, R.Quek, V.K.Lee Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010; 52:370-9; PMID:19720422; http://dx.doi.org/10.1016/j.jhep.2009.07.013.